Targeting Kras^g12c -mutant cancer with a mutation-specific inhibitor

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RAS genes (H, N, KRAS) are the most frequently mutated oncogenes in cancer.
• KRAS mutations, particularly G12C, are prevalent in pancreatic, colorectal, and lung cancers, contributing significantly to cancer mortality.
• Decades of research targeting RAS proteins and their pathways have yielded limited success, with no approved KRAS-specific drugs.

Purpose of the Study:

• To review the history of RAS-targeting efforts.
• To discuss the discovery and mechanism of MRTX849, a novel KRAS G12C inhibitor.
• To highlight the therapeutic potential of MRTX849 for KRAS G12C-mutant cancers.

Main Methods:

• Identification and characterization of MRTX849 as a potent and selective covalent inhibitor of KRAS G12C.
• Assessment of MRTX849's mechanism of action, including inhibition of GTP-loading and downstream signaling.
• Evaluation of MRTX849's efficacy in preclinical cancer models (cell line xenografts, patient-derived xenografts) and early clinical trials.

Main Results:

• MRTX849 selectively targets the mutant cysteine in GDP-bound KRAS G12C.
• The drug effectively inhibits KRAS G12C-driven signaling and suppresses tumor growth in preclinical models.
• MRTX849 has demonstrated objective responses in patients with KRAS G12C-mutant lung and colorectal cancers, both as a monotherapy and in combination with other agents.

Conclusions:

• MRTX849 represents a significant advancement in the development of targeted therapies for KRAS G12C-mutant cancers.
• This drug offers a long-awaited opportunity for selective inhibition of mutant KRAS, with promising clinical outcomes.
• Further investigation and clinical application of MRTX849 are warranted for patients with specific KRAS mutations.